特发性膜性肾病患者抗β2-糖蛋白 I 抗体与补体激活的相关性。

The correlation of anti-β2-glycoprotein I antibody with complement activation in patients with idiopathic membranous nephropathy.

机构信息

Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Key Laboratory of Kidney Disease Prevention and Control Technology, Institute of Nephrology, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, People's Republic of China.

Division of Nephrology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, People's Republic of China.

出版信息

Int Urol Nephrol. 2021 May;53(5):955-959. doi: 10.1007/s11255-020-02698-2. Epub 2021 Jan 3.

DOI:10.1007/s11255-020-02698-2

PMID:33392885

Abstract

PURPOSE

This study evaluated the correlation of anti-β2-glycoprotein I (anti-β2-GPI) antibodies with complement activation in patients with idiopathic membranous nephropathy (IMN).

METHODS

Thirty-two IMN patients with positive anti-β2-GPI antibody were enrolled, and 32 age- and sex-matched IMN patients with negative anti-β2-GPI antibody were randomly enrolled as controls. The frozen serum samples of these 64 patients were collected for detection of anti-phospholipase A2 receptor (PLA2R) antibody and the activity of three complement pathways. Paraffin specimens of the kidney tissues of these 64 patients were collected for immunohistochemical staining of C4d.

RESULTS

IMN patients with positive anti-β2-GPI antibody had a significant decline of the residual complement activity of alternative pathway than those with negative anti-β2-GPI antibody (37.4 ± 21.2% vs 65.7 ± 50.5%, P = 0.021). The positive rate of kidney C4d staining in IMN patients with and without anti-β2-GPI was 65.6 and 81.2%, with no significant difference (P = 0.257). Patients with and without anti-β2-GPI had the same positive rate of anti-PLA2R antibody.

CONCLUSION

Anti-β2-GPI antibody was associated with alternative complement activation in patients with IMN.

摘要

目的

本研究评估了特发性膜性肾病（IMN）患者抗β2-糖蛋白 I（抗β2-GPI）抗体与补体激活的相关性。

方法

纳入 32 例抗β2-GPI 抗体阳性的 IMN 患者，并随机纳入 32 例年龄和性别匹配的抗β2-GPI 抗体阴性的 IMN 患者作为对照组。收集这 64 例患者的冷冻血清样本检测抗磷脂酶 A2 受体（PLA2R）抗体和三种补体途径的活性。收集这 64 例患者的肾组织石蜡标本进行 C4d 的免疫组织化学染色。

结果

抗β2-GPI 抗体阳性的 IMN 患者替代途径残余补体活性明显低于抗β2-GPI 抗体阴性的患者（37.4±21.2%比 65.7±50.5%，P=0.021）。抗β2-GPI 阳性和阴性的 IMN 患者肾组织 C4d 染色的阳性率分别为 65.6%和 81.2%，差异无统计学意义（P=0.257）。有和没有抗β2-GPI 的患者抗 PLA2R 抗体的阳性率相同。